Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States | Adolescent Medicine | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
1.
Lookingbill  DP.  Yield from a complete skin examination: findings in 1157 new dermatology patients.  J Am Acad Dermatol. 1988;18(1, pt 1):31-37.PubMedGoogle ScholarCrossref
2.
Jemec  GB, Heidenheim  M, Nielsen  NH.  The prevalence of hidradenitis suppurativa and its potential precursor lesions.  J Am Acad Dermatol. 1996;35(2, pt 1):191-194.PubMedGoogle ScholarCrossref
3.
Jemec  GB.  The symptomatology of hidradenitis suppurativa in women.  Br J Dermatol. 1988;119(3):345-350.PubMedGoogle ScholarCrossref
4.
von der Werth  JM, Williams  HC.  The natural history of hidradenitis suppurativa.  J Eur Acad Dermatol Venereol. 2000;14(5):389-392.PubMedGoogle ScholarCrossref
5.
Revuz  JE, Canoui-Poitrine  F, Wolkenstein  P,  et al.  Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies.  J Am Acad Dermatol. 2008;59(4):596-601.PubMedGoogle ScholarCrossref
6.
Jemec  GB.  Clinical practice: hidradenitis suppurativa.  N Engl J Med. 2012;366(2):158-164.PubMedGoogle ScholarCrossref
7.
Vinding  GR, Miller  IM, Zarchi  K, Ibler  KS, Ellervik  C, Jemec  GB.  The prevalence of inverse recurrent suppuration: a population-based study of possible hidradenitis suppurativa.  Br J Dermatol. 2014;170(4):884-889.PubMedGoogle ScholarCrossref
8.
Cosmatos  I, Matcho  A, Weinstein  R, Montgomery  MO, Stang  P.  Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States.  J Am Acad Dermatol. 2013;69(5):819.PubMedGoogle ScholarCrossref
9.
Shlyankevich  J, Chen  AJ, Kim  GE, Kimball  AB.  Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis.  J Am Acad Dermatol. 2014;71(6):1144-1150.PubMedGoogle ScholarCrossref
10.
Shahi  V, Alikhan  A, Vazquez  BG, Weaver  AL, Davis  MD.  Prevalence of hidradenitis suppurativa: a population-based study in Olmsted County, Minnesota.  Dermatology. 2014;229(2):154-158.PubMedGoogle ScholarCrossref
11.
Explorys Inc. The IBM Explorys Platform. Somers, NY: IBM Corporation; June 2016. https://public.dhe.ibm.com/common/ssi/ecm/hp/en/hps03052usen/HPS03052USEN.PDF. Accessed January 18, 2016.
12.
US National Library of Medicine Unified Medical Language System (UMLS). Systematized Nomenclature of Medicine—ClinicalsTerms (SNOMED CT). https://www.nlm.nih.gov/research/umls/Snomed/snomed_main.html. Published March 1, 2016. Accessed October 10, 2016.
13.
Nelson  SJ, Zeng  K, Kilbourne  J, Powell  T, Moore  R.  Normalized names for clinical drugs: RxNorm at 6 years.  J Am Med Inform Assoc. 2011;18(4):441-448.PubMedGoogle ScholarCrossref
14.
McDonald  CJ, Huff  SM, Suico  JG,  et al.  LOINC, a universal standard for identifying laboratory observations: a 5-year update.  Clin Chem. 2003;49(4):624-633.PubMedGoogle ScholarCrossref
15.
Kaelber  DC, Foster  W, Gilder  J, Love  TE, Jain  AK.  Patient characteristics associated with venous thromboembolic events: a cohort study using pooled electronic health record data.  J Am Med Inform Assoc. 2012;19(6):965-972.PubMedGoogle ScholarCrossref
16.
Kim  CH, Al-Kindi  SG, Jandali  B, Askari  AD, Zacharias  M, Oliveira  GH.  Incidence and risk of heart failure in systemic lupus erythematosus.  Heart. 2017;103(3):227-233.PubMedGoogle ScholarCrossref
17.
US Census Bureau. Projections of the Total Resident Population by 5-Year Age Groups, and Sex with Special Age Categories: Middle Series, 1999 to 2000 (NP-T3-A): http://www.census.gov/population/projections/files/natproj/summary/np-t3-a.pdf. Published January 13, 2000. Accessed October 31, 2016.
18.
Wilson  EB.  Probable inference, the law of succession, and statistical inference.  J Am Stat Assoc. 1927;22(158):209-212.Google ScholarCrossref
19.
Fay  MP, Feuer  EJ.  Confidence intervals for directly standardized rates: a method based on the gamma distribution.  Stat Med. 1997;16(7):791-801.PubMedGoogle ScholarCrossref
20.
Khalsa  A, Liu  G, Kirby  JS.  Increased utilization of emergency department and inpatient care by patients with hidradenitis suppurativa.  J Am Acad Dermatol. 2015;73(4):609-614.PubMedGoogle ScholarCrossref
21.
Kirby  JS, Miller  JJ, Adams  DR, Leslie  D.  Health care utilization patterns and costs for patients with hidradenitis suppurativa.  JAMA Dermatol. 2014;150(9):937-944.PubMedGoogle ScholarCrossref
Original Investigation
August 2017

Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States

Author Affiliations
  • 1Department of Dermatology, Hofstra Northwell School of Medicine, New Hyde Park, New York
  • 2Department of Dermatology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
JAMA Dermatol. 2017;153(8):760-764. doi:10.1001/jamadermatol.2017.0201
Key Points

Questions  What is the prevalence of hidradenitis suppurativa in the United States, and does prevalence vary by demographic group?

Findings  In this population-based analysis, the overall point prevalence of hidradenitis suppurativa was 0.10%, or 98 per 100 000 persons. Prevalence was highest among women (137 per 100 000), those aged 30 to 39 years (172 per 100 000), and African American (296 per 100 000) and biracial (218 per 100 000) patient groups.

Meaning  Hidradenitis suppurativa is an uncommon, but not rare, disease in the United States that disproportionately affects female patients, young adults, and African American and biracial patients.

Abstract

Importance  The true prevalence of hidradenitis suppurativa (HS) is unknown.

Objective  To establish standardized overall and group-specific prevalence estimates for HS in the United States.

Design, Setting, and Participants  This retrospective analysis included a demographically heterogeneous population-based sample of more than 48 million unique patients across all US census regions. As of October 27, 2016, a total of 47 690 patients with HS were identified using electronic health record data.

Main Outcomes and Measures  Standardized overall point prevalence for HS and sex-, age-, and race-specific prevalence estimates of HS in the general US population.

Results  Of the 47 690 patients with HS (26.2% men and 73.8% women), the overall HS prevalence in the US population sample was 0.10%, or 98 per 100 000 persons (95% CI, 97-99 per 100 000 persons). The adjusted prevalence in women was 137 per 100 000 (95% CI, 136-139 per 100 000), more than twice that of men (58 per 100 000; 95% CI, 57-59 per 100 000; P < .001). The prevalence of HS was highest among patients aged 30 to 39 years (172 per 100 000; 95% CI, 169-275 per 100 000) compared with all other age groups (range, 15-150 per 100 000; P < .001). Adjusted HS prevalences among African American (296 per 100 000; 95% CI, 291-300 per 100 000) and biracial (218 per 100 000; 95% CI, 202-235 per 100 000) patients were more than 3-fold and 2-fold greater, respectively, than that among white patients (95 per 100 000; 95% CI, 94-96 per 100 000; P < .001).

Conclusions and Relevance  Hidradenitis suppurativa is an uncommon, but not rare, disease in the United States that disproportionately affects female patients, young adults, and African American and biracial patients.

×